982
Views
34
CrossRef citations to date
0
Altmetric
Review

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

, &
Pages 125-143 | Published online: 27 Sep 2022

Abstract

Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The α-glucosidase inhibitor acarbose, and the α-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.

Prevalence and impact of obesity

A positive energy balance resulting from a chronic disparity between the intake of energy and its expenditure leads to weight gain and eventually obesity. Currently, the global tendency to gain weight poses a major menace to world health. Adiposity (overweight and obesity) constitutes a key risk factor for a variety of adulthood chronic disorders such as dyslipidemia, high blood pressure, type II diabetes, cardiovascular disease, osteoarthritis and some forms of cancer.Citation1 In the European Region, 2% to 8% of health costs could be attributable to obesity.Citation2 Obesity can no longer be considered only a problem of developed, ‘Westernized’, high income countries. On every continent developing countries are experiencing similar increases in the prevalence of overweight and obesity within their population, particularly in urban settings.

Currently, a body mass index (BMI) of 30 kg/m2 or greater defines adult obesity, and between 25 and 29.9 kg/m2 is classified as overweight. However, lower cut off points should be used in certain populations at greater risk of obesity related diseases. In 2005, the World Health Organization (WHO) reported that 1.6 billion adults could be categorized as overweight whilst at least 400 million adults were considered obese.Citation3 The WHO predicted that over the next ten years global rates of overweight and obesity would double, and by 2015 roughly 2.3 billion adults would be overweight and over 700 million obese. Europe has followed the global trend – since 1980 the prevalence of obesity has tripled, with levels continuing to rise at an alarming rate.

For intervention, the most common and widely advocated approaches remain changes in lifestyle, specifically dieting and exercise. Achieving significant weight loss is a difficult task and although some individuals manage to lose weight in the short term, for most people maintaining a lower body weight in the long term proves remarkably difficult.Citation4,Citation5 Drug therapy offers a reasonable option to overcome obesity when given as an adjunct to life style interventions such as dietary counseling, behavioral modifications and structured exercise.Citation6,Citation7 Modest weight reduction (5% to 10% of total body weight) in patients with obesity-associated medical complications produces beneficial health outcomes. A reduction of 5 to 10 kg of body weight in moderately obese patients reduces blood pressure and cholesterol levels, and improves glycemia along with a reduced risk of undesirable clinical outcomes including myocardial infarction, stroke and cardiovascular- related deathCitation8 and increases longevity.Citation9

The phenomenon of weight gain suggests that the homeostatic mechanisms regulating energy homeostasis are insufficient to cope with our current obesity promoting environment. However, boosting inhibitory homeostatic feedback could re-establish effective homeostatic control of energy balance and even induce weight loss. Consequently, the mechanisms underpinning the regulation of appetite and energy regulation have received particular attention, notably for the development of anti-obesity drugs.Citation10,Citation11 These include drugs that reduce appetite and/or enhance satiety or drugs that stimulate energy expenditure thereby restoring energy balance. Although providing a rich source of drug targets for weight control, this approach ignores the possibility that over-consumption associated with obesity results from the stimulatory effect of the food environment rather than any particular biological deficit (such as in post ingestive satiety from the gut or increased adiposity signals from body fat stores). The withdrawal of appetite-suppressing drugs that act on the central nervous system such as fenfluramine, d-fenfluramine, rimonabant and sibutramine (withdrawn in Europe but still available in the US), suggests that targeting energy regulation systems for weight control is not without problems. Even peripheral appetite targets such as gut peptides implicated in the processes of satiation and satiety such as glucagon-like peptide-1 (GLP)-1 and peptide YY (PYY) are difficult to administer and may induce nausea.

Nonetheless, drugs acting in the periphery provide a viable alternative for weight management and other pharmacological approaches to the treatment of obesity have proved successful, specifically drugs that affect the absorption or partitioning of nutrients.Citation12 A lipase inhibitor is currently the only prescription medicine available in Europe for obesity treatment. This review will focus on drugs that have, as a potential mechanism, the disruption of fat and carbohydrate absorption. and summarize the doses and effects found in vitro and in vivo studies.

Table 1 Effective in vitro doses and target enzymes of inhibitors

Table 2 Enzyme inhibitors: doses and in vivo effects

Dietary fat digestion and absorption

Lipids are fundamental components of all living organisms, and they are calorically dense thus representing an important constituent of human nutrition (approximately 40% of daily energy intake). Dietary fats are absorbed in the intestine and they function as an energy supply, thermal regulators, membrane constituents, energy storage and some play an important role in body function as essential fatty acids and fat-soluble vitamins.Citation13 The human intestine is able to completely absorb approximately 95% of ingested fat.Citation14 Given the efficient absorption of dietary fat it is not surprising that long term intake of a high fat diet is readily converted to adipose tissue particularly in those with low levels of physical activity.Citation15 In such a scenario it is logical to assume that the modification of fat absorption could be a potential target to treat obesity and prevent further weight gain.

The main fat constituents (90%) of a typical Western diet are triacylglycerols or triglycerides (TG). TG consist of a single molecule of glycerol, attached by ester bonds to three fatty acids. TG cannot be absorbed; therefore, intestinal enzymes must hydrolyze the ester bonds on the glycerol backbone in order for the molecule to be absorbed. The products of this hydrolysis are mainly free fatty acids (FFA) and 2- monoglycerides (2-MG) which can be absorbed by the duodenum. In vivo TG hydrolysis is catalyzed by several digestive lipases. There are several human lipases which include the pre-duodenal (lingual and human gastric lipase (HGL)) and the extra-duodenal (pancreatic, hepatic, lipoprotein and endothelial) lipases.Citation16

Lingual lipase is secreted by a serous gland at the back of the tongue and initiates fat digestion.Citation17 HGL is secreted by the chief cells of the fundic mucosa of the stomach, this enzyme is active at a broad pH range (3 to 6) and is stable even at the low pH present in the stomach.Citation18 The acinar cells of the pancreas synthesize and secrete several lipolytic enzymes such as colipase-dependent lipase, classical pancreatic lipase or triacylglycerol acyl hydrolase (HPL), pancreatic lipase related-protein 1 and 2 (HPLRP1, HPLRP2), carboxyl ester hydrolase (also known as bile salt stimulated lipase, carboxyl ester lipase, cholesterol esterase, cholesterol ester lipase, human milk lipase, monoglyceride lipase and pancreatic non-specific lipase) and phospholipase A2.Citation17,Citation19 Cholesterol esters, lipidic vitamin esters, monoglycerides, diglycerides, TG, and phospholipids are hydrolyzed mainly by carboxyl ester hydrolase. The pancreas also secretes colipase, a factor that is necessary to optimize pancreatic lipase activity. Colipase binds to bile acid micelles and phospholipid-covered emulsions. Once bound to these surfaces, colipase facilitates the interaction between pancreatic lipase and the surface of emulsified lipid droplets.Citation20 Although HPLRP1 and -2 share a high degree of structural homology and sequence with HPL,Citation21 their role in lipid digestion has not been fully clarified. It is known that under physiological conditions HPLRP1 does not exert lipolytic activity.Citation21,Citation22 HPLRP2 hydrolyzes galactolipids,Citation23,Citation24 phospholipids and TG at a low rate,Citation23 and retinyl ester.Citation25 HPLRP2 does not need colipase to be active.Citation23

The hydrolysis of dietary TG starts in the stomach by the catalytic action of HGL. The secretion of HGL is induced by mechanical stimulation of the stomach, ingestion of food or sympathetic activation.Citation17 HGL hydrolyzes 5% to 40% of ingested TG,Citation26 mainly generating FFA, diglycerides, and a few 2-MG molecules.Citation27 Gastric lipolysis is crucial for the continuation of the digestion process in the duodenum by HPL. Gastric lipolysis ensures: (i) lipid emulsification which creates the lipid–water interface needed for effective lipolysis in the duodenum,Citation27Citation29 (ii) the generation of long-chain FFA which, once in the duodenum, will stimulate the release of cholecystokinin (CCK) and HPL secretion, slowing down gastric emptying,Citation18 and (iii) the generation of diglycerides, which are hydrolyzed more effectively than TG.Citation30 Therefore, the impact of HPL inhibition on lipid absorption is limited by the activity of HGL.Citation31 The hydrolysis of TG persists in the duodenum by means of the combined actions of HGL (HGL is responsible for further lipolysis contributing 7.5% to total lipolysis in the duodenum), HPL and bile salts. HPL is the principal pancreatic lipolytic enzyme; it hydrolyzes 40% to 70% of TGCitation26,Citation28,Citation29 yielding 2-MG and long-chain saturated and polyunsaturated FFA as the lipolytic products.Citation16,Citation31,Citation32 For full activity under physiological conditions, HPL requires the presence of another pancreatic exocrine protein: colipase. Colipase is secreted as a precursor molecule, in the presence of bile salts, pro-colipase binds, without inducing any conformational change, to the C-terminal domain of the HPL molecule.Citation33 In order to be absorbed, bile-derived mixed micelles convert FFA and 2-MG into soluble aggregates. These micelles transport these lipolytic products from the intestinal lumen to the intestinal walls.Citation13,Citation14 Once in contact with the enterocyte, the molecules are transported across the cell membrane. The enterocyte re-esterifies 2-MG and FFA into TG, assembles them into chylomicrons and then secretes these into the lymphatic system in order make them bioavailable.Citation19,Citation30,Citation34 Lipolysis rates and consequently FFA supply to the body can be affected by several factors such as lipase levels and activity, physicochemical properties of dietary lipids, and the presence of inhibitors or enhancers.

Carbohydrate digestion and absorption

In humans, between 40% and 80% of total caloric intake is accounted for by carbohydrates in their various forms, making them the most important energy source. According to their chemical structure carbohydrates can be classified into absorbable (undigested), digestible, fermentable and non-fermentable forms.Citation35 Absorbable carbohydrates (monosaccharides, comprising a single unit such as glucose, galactose, fructose, xylose and ribose) by definition do not need to be digested in order to be transported into the body. However, once a carbohydrate comprises two or more units, it has to be enzymatically digested for it to be absorbed. In the human diet, the main digestible carbohydrates comprise disaccharides such as sucrose (sugar) and lactose, and larger polysaccharides such as starch which constitute a main source of calories in most Western diets. In contrast, fermentable carbohydrates cannot be digested as enzymes cannot readily break the inter saccharide bonds. However, once in the colon these carbohydrates are readily metabolized by colonic bacteria through the process of fermentation. Similarly, if digestible carbohydrates such as sucrose and lactose are maldigested or malabsorbed, they will also be fermented in the large intestine. The main end products of carbohydrate fermentation are short-chain fatty acids (acetate, propionate, and butyrate) and gases (carbon dioxide, hydrogen, and methane).Citation36 They can be absorbed in the large intestine (providing energy), used as a bacterial substrate, released as flatus, or excreted as biomass in the feces. Some carbohydrates (such as components of plant cell walls) are neither digested/absorbed nor fermented. They pass through the gastrointestinal (GI) tract mostly unchanged and are eliminated in the feces.

The digestion of carbohydrates begins in the mouth by the action of salivary α-amylase, which hydrolyzes the α-1,4 bonds in starch, the products of this process are maltose, maltriose, and small dextrins. The starch digestion process continues in the small intestine by the action of pancreatic α-amylase. The digestion process is completed by enzymes in the brush border of the small intestine (maltase, sucrase, and lactase, also known as disaccharidases or α-glucosidases) which yields the absorbable monosaccharides glucose, fructose, and galactose. A small proportion of monosaccharides can be absorbed passively; however, a carrier protein is required to absorb the amount ingested in a normal diet.Citation37

Drugs that interfere with lipid absorption

Although lipid metabolism is balanced to maintain homeostasis, high-fat diets tend to induce overconsumption and as a consequence, weight gain. This is mainly due to their high energy content and their low potential for inducing satiety.Citation38,Citation39 It has been proposed that in the vast majority of cases, overweight and obesity are the consequences of exaggerated consumption of fat rather than carbohydrates.Citation40 This does not mean that obesity is not also associated with the consumption of refined sweet carbohydrates, but rather that the intake of this form of carbohydrate is invariably coupled with the intake of dietary fat (in sweet snack foods, sodas and desserts) along with the consumption of high fat savory food items (these often also contain considerable amounts of refined carbohydrates). Given the central role of dietary fat in weight gain, a rational strategy would be to reduce the proportion of calories derived from fat in the diet. In addition to altering dietary intake, the amount of fat entering the body can be reduced by targeting the enzymes involved in lipid digestion and absorption pathways.Citation32 Such an approach would have the advantage of reducing energy entering the body without targeting the central nervous system, avoiding the side effect issues that have dogged many appetite-suppressing agents.Citation41

The inhibition of fat digestion and absorption is not without side effect issues. As detailed later, GI distress and vitamin deficiencies remain a concern with current treatments. However, humans can tolerate a certain degree of inhibition of fat absorption, sufficient to prevent a significant amount of energy entering the body. Given that fat contains 9 kcal/g, the inhibition of the absorption of 30 g/day would produce a daily deficit of nearly 300 kcal.Citation42 This, in addition to a mildly hypocaloric, well-balanced diet, could theoretically produce weight loss of 0.5 kg/week. Once the excess weight is lost, the therapy could be modified for long-term weight maintenance. For the treatment of hyperlipidemia alone, perhaps even less limited inhibition of fat absorption could produce desirable results. Moreover, the benefits of reducing fat absorption are not restricted to weight loss. Specific reduction of lipid levels in subjects with hyperlipidemias would lead to health benefits beyond those expected through reduction in caloric intake and weight loss alone.

HPL isolated C-terminal domain

The fact that HPL activates when it forms a complex between its C-terminal region and colipase has brought attention to a relatively new strategy to reduce the activity of HPL.Citation43 The isolated C-terminal domain has shown potential HPL inhibitory activity, both in vitro Citation44 and in rodentsCitation45 it behaves as a colipase lure. Studies in humans are required to test the effectiveness of this strategy.

Cetilistat

Cetilistat (ATL-962, Alizyme®; Takeda Pharmaceutical) was developed with the aim of creating a drug similar to orlistat (see below) but without its side effects. Although cetilistat has shown inhibitory activity for both rat and HPL (IC50 of 54.8 nmol/L and 5.95 nmol/L respectively) it can be seen from the IC50 that this component is a much more efficient inhibitor of HPL than rat lipase. Administration of cetilistat (3 to 100 mg/kg) to diet-induced obesity (DIO) rats exposed to oral fat loading reduced plasmatic TG elevation with a correspondent increase in fat excretion in a dose dependent manner. This reduced body weight gain and white adipose tissue weight.Citation46 A phase I study showed that cetilistat increases fecal fat excretion in a similar way to orlistat but with a better reported tolerability.Citation47 Phase IIb studies showed that its administration (180 to 720 mg/day) to obese individuals with and without type II diabetes on a hypocaloric moderate fat diet produced significant weight loss when compared to subjects receiving placebo.Citation48,Citation49 The reported adverse effects were similar to those in the placebo group. Despite its reported efficacy and reduced adverse event profile, further development of cetilistat for obesity treatment has been discontinued by Takeda.

Lipase inhibitors from plants

In the continuing search for novel anti-obesity agents, numerous plant derived phytochemicals have been screened for potential lipase inhibition activity. A recent extensive study examined 132 extracts from 106 plant species, used either as foods or medicinal herbs, screening them for pancreatic lipase inhibition activity.Citation50 Surprisingly, the majority of extracts, 100 in total, exhibited some degree of inhibitory activity. All extracts from plants belonging to Brassicaceae, Ericaceae, Fabaceae, Rosaceae and Solanaceae showed inhibitory activity. Twenty-six extracts inhibited lipase activity by at least 40%, of which 10 exhibited over 70% inhibitory activity. All extracts from apples exhibited more than 70% inhibitory activity. The current review classifies these botanically derived inhibitors into the following chemical classes.

Saponins

Saponins are phytochemicals which can be found in the roots and rhizomes of most vegetables, beans and herbs. Saponins are glycosides known for their soap-like foaming ability when mixed with water. This foaming ability results from the combination of a lipophylic sapogenin and a hydrophilic sugar part.Citation51 Certain saponins such as oleanane, lupine and dammarane-type can inhibit pancreatic lipase activity and therefore have potential as treatments that could prove effective for obesity and related disorders.Citation52Citation54 However, the clinical potential of saponins remains difficult to judge with such limited clinical data available.

Acanthopanax senticosus (Rupr. Maxim) Harms

A. senticosus, also known as Siberian Ginseng or Eleutherococcus senticosus, is a shrub commonly found in the northeast of Asia. Crude A. senticosus extracts have been used to treat physiological changes induced by stress,Citation55,Citation56 some allergic and inflammatory conditions,Citation57,Citation58 cancer,Citation59 chronic bronchitis, hypertension, ischemic heart disease, and gastric ulcers.Citation60 So far, 26 triterpenoid saponins have been isolated from the leaves and fruits of A. senticosus Citation52 among which ciwujianoside C1, tauroside H1, 3-O- α-L-rhamnopyranosyl-(1→2)- α-L-arabinopyranosyl mesembryanthemoidigenic acid, acanthopanaxoside C, acanthopanaxoside E, silphioside F, copteroside B, hederagenin 3-O- β-D glucuronopyranoside 6′-O-methyl ester and gypsogenin 3-O- β-D-glucuronide, sessiloside and chiisanoside exhibit pancreatic lipase inhibitory activity in vitro with IC50 values ranging from 0.22 to 0.29 mM.Citation52,Citation61 Studies performed in vivo have shown that in DIO ratsCitation62 and C57BL/6J mice, administration of an A. senticosus extract (12 mg/kg for 12 weeks) decreased the deposition of abdominal fat and improved associated lipid parameters, such as increasing serum high-density lipoprotein (HDL) cholesterol, and decreasing serum TG, low-density lipoprotein (LDL) cholesterol, and hepatic TG.Citation63 In a placebo controlled study, administration of concentrated extracts of A. senticosus (1500 mg/day for 6 months) to postmenopausal women decreased serum LDL levels and LDL/HDL ratios without associated side effects.Citation64 However, since A. senticosus extracts have several mechanisms of action including the inhibition of hepatic lipogenic enzymes and glucose 6-phosphatase,Citation65 the reduction of LDL levels is probably the result of a combination of effects. The effects of A. senticosus extract on body mass and body composition remain to be demonstrated.

Acanthopanax sessiliflorus sessiloside and chiisanoside

These are lupine-type saponins found in the leaves of A. sessiliflorus. In vitro studies have shown that both sessiloside and chiisanoside inhibit HPL activity in a dose-dependent manner, with IC50 values of 0.36 and 0.75 mg/mL, respectively.Citation53 In mice, simultaneous administration of oil and chiisanoside (100 and 300 mg/kg) decreased plasma TG levels and increased the amount of undigested TG in the intestinal lumen.Citation66 No clinical data are available on A. sessiliflorus.

Aesculus turbinata escins

A. turbinata (Japanese horse chestnut) is a medicinal plant widely distributed in north western China. Its dried ripe seeds have been employed as a carminative, stomachic, and analgesic for the treatment of distension and pain in the chest and abdomen.Citation67 The saponins extracted from the seeds are called escins. Recently, escins have been reported to show inhibition of pancreatic lipase activity (IC50 of 24 mg/mL).Citation68,Citation69 Administration of escins (0.1% to 0.5% of diet) to mice fed a high fat diet prevented body weight gain without altering caloric intake. An increase in the levels of undigested fat in the mice feces confirmed effective inhibition of fat digestion in vivo.Citation70 However, to date there are no published clinical data on these effects in humans.

Chinese tea plant saponins

Studies performed with crude saponins extracted from the flower buds of the Chinese tea plant Camellia sinensis have shown that in mice they accelerate GI transit and also exert an inhibitory effect on pancreatic lipase with an IC50 of 0.091 mg/mL. The main components responsible for these effects are the chakasaponins I, II, and III which inhibit pancreatic lipase with IC50 values of 0.17 to 0.53 mM. Such compounds could be valuable in the prevention of obesity, but studies assessing their effect in HPL are needed to assess their potential.Citation71

Dioscorea nipponica

D. nipponica Makino is a herb that grows in the mountainous areas of the Korean peninsula. It has long been used as a popular remedy for the treatment of several diseases including asthma, rheumatoid arthritis and bronchitis.Citation72 The extract of D. nipponica appears to inhibit porcine pancreatic lipase activity with IC50 values of 5 to 10 mg/mL. Dioscin and its aglycone diosgenin are the result of further purification processes. When administered to mice, both components have been shown to suppress increases of blood TG following oral administration of corn oil.Citation72 Rats fed a high fat diet containing 5% of D. nipponica had significantly lower body weight gain that their control counterparts. This was accompanied by decreases in blood TG, very-low-density lipoproteins (VLDL) and LDL.Citation72 The effects of D. nipponica on body weight have yet to be proven in a clinical study.

Oolong tea saponins

Three types of tea, green, oolong and black are used all over the world as traditional healthy drinks. Green and oolong tea have been reported to exert anti-obesity and hypolipidemic actions. Black tea also contains many active ingredients;Citation73 however some may not survive processing. These teas contain several different active ingredients that may exert anti-obesity actions through various mechanisms. Oolong tea contains two saponins (theasaponins E1 and E2) that seem to competitively inhibit pancreatic lipase activity with Km and Vmax values of 1.42 mg/mL and 476.2 nkat/L respectively. The Ki value of tea saponin is 0.25 mg/mL.Citation73,Citation74 However, to date no studies of in vivo activity of these saponins have been reported.

Panax japonicus chikusetsusaponins

The rhizomes of P. japonicus C.A. Meyer (Japanese name; Chikusetsuninjin), have been used as a folk medicine for hypertension, arteriosclerosis and diabetes.Citation75 In vitro total chikusetsusaponins as well as chikusetsusaponin III, 28-deglucosyl-chikusetsusaponin IV and 28-deglucosylchikusetsusaponin vs inhibit pancreatic lipase activity at concentrations of 125 to 500 μg/mL.Citation76 One study showed that the administration of total chikusetsusaponins (1% to 3% in diet) significantly suppressed weight gain in DIO mice.Citation76 This effect was independent of energy intake and correlated with a significant reduction in parametrial adipose tissue weight. In addition, a reduction of plasma TG levels was observed.Citation76 Clinical studies on the effects of chikusetsusaponins on body composition or body mass have yet to be published.

Platycodin saponins

Platycodin saponins are the main constituents of Platycodi radix. Platycodi radix is the root of Platycodon grandiflorum A. DC (Campanulaceae), commonly known as Doraji.Citation77 Some Asian cultures use Platycodi radix in cooking and also as a traditional oriental medicine ingredient. Some evidence shows that Platycodi radix extracts possess some health benefits such as the improvement of hypercholesterolemia and hyperlipidemia.Citation78 The saponin-rich fraction of Platycodi radix has an inhibitory effect on HPL and this seems to correlate with anti-obesity actions.Citation79Citation82 Among the various saponins, platycodin D possesses the strongest HPL inhibitory activity with a Ki of 0.18 mM.Citation82 Nevertheless, a study by Zhao et alCitation83 found that in rats, the decrease in body weight correlated with decrease in caloric intake, an effect not obviously attributable to lipase inhibition. They ascribed this effect to the ability of Platycodin saponins to reduce gastric secretion,Citation84 which in turn would slow gastric digestion, decreasing subsequent food intake. These results, taken together, suggest that Platycodin saponins provide a potential alternative treatment for both obesity and hyperlipidemia.Citation80,Citation81 However, further data showing replication of these effects in humans are needed.

Sapindus rarak DC

S. rarak is a tree found in South and Southeast Asian countries. The pericarps have anti-pruritic actions.Citation85 A recent in vitro study has shown that the methanolic extract from S. rarak pericarps exerts pancreatic lipase inhibitory activity (IC50 = 614 μg/mL). This extract contains several saponins of which rarasaponins I and II and raraoside A inhibited pancreatic lipase with IC50 of 131 μM, 172 μM and 151 μM respectively.Citation86 The in vivo effects of S. rarak saponins remains yet to be investigated.

Scabiosaponins

Scabiosa tschiliensis Grun. (Dipsacaceae) is a perennial herb widely distributed in Mongolia and China. S. tschiliensis flowers are traditionally used as a remedy for headache, fever, cough, and jaundice.Citation87 In vitro studies have reported that scabiosaponins E, F, G and I, hookeroside A and B, and prosapogenin 1b inhibit HPL. Of these, prosapogenin 1b reportedly possesses the greater inhibitory activity at a concentration of 0.12 mg/mL. This dose produced lipase inhibitory activity comparable to 0.005 mg/mL of orlistat in the same model.Citation87 The fact that to date no studies in vivo have been reported could be due to the difficulties in isolating these compounds. However, recently scabiosaponins E, F, and G have been successfully synthesized.Citation88

Polyphenols

Polyphenols are chemical compounds characterized by the presence of more than one phenol unit or building block per molecule. Fruit skins contain high levels of polyphenols. The health benefits of specific polyphenols are well-documented. Polyphenols possess antioxidant actions and are also able to inhibit digestive enzymes, these two actions could lower the risk of cardiovascular disease and cancer.Citation89 Naturally occurring polyphenols, and in particular catechins and condensed tannins isolated from various plant sources, have been shown to inhibit digestive enzymes including lipase and α-amylase in vitro Citation90Citation92 and therefore have some potential in the management of obesity.

Apple polyphenols

Apples contain several phenolic substances (ie, chlorogenic acid, (+)-catechin, epicatechin, phloridzin, rutin, and procyanidins (condensed tannins).Citation93 Procyanidins in apples are mainly composed of various polymerized catechins. Apples and their polyphenol (AP) extract have several biological activities such as antioxidant,Citation94 anti-allergyCitation95 and anti-tumor activity.Citation96 In a recent study performed by Sugiyama et alCitation97 it was found that AP inhibited pancreatic lipase activity in a dose-dependent manner with an IC50 value of 5.6 μg/mL. In addition, the procyanidin fractions extracted from AP also inhibited pancreatic lipase activity in a dose-dependent manner with an IC50 value of 1.4 μg/mL. In mice, AP administration (200 mg/kg) significantly decreased plasma TG after corn oil loading. The procyanidin fraction also tended to inhibit TG absorption as compared with the control group. Administration of AP (600 mg) containing capsules to humans inhibited TG elevation after TG load when compared to subjects receiving placebo. No side effects were reported.Citation97

Cassia mimosoides L. var nomame Makino (Nomame Herba)

C. mimisoides is a leguminous plant grown in Japan and China. Its ethanol extract, CT-II, possesses a dose dependent inhibitory action on porcine lipase.Citation98 When administered to rats fed high fat diets, CT-II (1% to 3.5% of diet) dose dependently suppressed body weight gain, and lowered parametrial fat and liver weight when compared to control animals.Citation98 The effects of CT-II on body weight in humans have yet to be reported.

Grape seed extracts

Grape seeds and skins contain a variety of health-promoting polyphenols, also known as condensed tannins or proanthocyanidins. Citation99 Currently these polyphenols are the focus of research to elucidate their putative beneficial effects.Citation100 Grape seed extract at a concentration of 1 mg/mL inhibits 80% of lipase activity.Citation101 Importantly, in vivo these extracts seem to lack toxicity. Further studies in animal models are needed to evaluate it potential as a weight loss product.Citation102

Terpenes

Terpenes are a large class of hydrocarbons, produced by a broad variety of plants. Chemical modification of terpenes yields terpenoids. Both terpenes and terpenoids are the main constituents of the essential oils of many plants. These include carnosic acid, carnosol, crocin and crocetin.

Carnosic acid and carnosol

Carnosic acid and carnosol are compounds extracted from the leaves of Salvia officinalis L. (sage). Both substances exert inhibitory activity on pancreatic lipase with IC50 values of 36 and 13 μM, respectively. Although carnosol possesses the stronger inhibitory activity in vitro, in vivo it seems to lack substantial effects. This has been attributed to its instability in suitable solvents.Citation103 Administration of carnosic acid (20 mg/kg/day, by mouth) to mice fed a high fat diet, it reduced body weight gain and the accumulation of epididymal fat.Citation104 To date studies in humans are lacking.

Crocin and crocetin

Gardeniae fructus is used as a Chinese traditional medicine mainly for its analgesic and antipyretic effects. It contains geniposide and crocin as main components.Citation105 These components exhibit antioxidant, antitumoral and neuroprotective effects.Citation106Citation108 In vitro, crocin and its metabolite crocetin potently inhibit pancreatic lipase. The most potent inhibitor was crocetin, with an IC50 value of 2.1 mg/mL.Citation109 In mice fed a high fat diet, crocetin and crocin inhibited the incremental increase in body weight compared with that of the control group. These compounds also significantly reduced epididymal fat pad mass. Their potency at a dose of 50 mg/kg is comparable with that of orlistat at a dose of 10 mg/kg.Citation109 Crocin and crocetin have yet to be tested in a clinical trial.

Lipase inhibitors derived from microbial sources

Lipstatin

Lipstatin, a compound isolated from Streptomyces toxytricini, is a very potent and selective irreversible inhibitor of pancreatic lipase. The IC50 of lipstatin for pancreatic lipase is 0.14 μM.Citation110 Tetrahydrolipstatin or orlistat (THL, Ro 18-0647, Xenical®; Hoffmann-La Roche, Basel, Switzerland) is a highly lipophilic hydrogenated derivative of lipstatin.Citation111,Citation112 Orlistat is a potent inhibitor of most mammalian lipases. Therapeutic doses of orlistat generally achieve around 35% inhibition of lipid digestion.Citation111,Citation113,Citation114 Thus as a consequence the undigested fat is not absorbed but excreted.Citation115 Beyond its lipase inhibition activity, orlistat reportedly does not significantly diminish the activity of other intestinal enzymes. Less than 1% of orlistat itself is absorbed, preventing inhibition of extra intestinal lipases.Citation116 When administered by intraduodenal infusion in a rat model it almost completely inhibited the absorption of cholesterol.Citation117 In humans, initial studies showed that orlistat administration at doses between 375 and 750 mg/day decreased fat absorption and therefore increased fat elimination which caused side effects related to the amount of fat in the diet. In both rodent and human participants short-term orlistat administration increases fecal fat loss which returns to baseline after cessation of dosing.Citation116,Citation118,Citation119 This product has been evaluated in many clinical studies for obesity treatment. After 1 year treatment, the combination of orlistat (120 mg taken three times daily just before feeding) and a hypocaloric diet produced a higher weight loss compared with placebo.Citation120,Citation121 Although the weight reduction from baseline was no greater than 10% (4% placebo subtracted),Citation120,Citation121 orlistat significantly decreased glycemia, glycated hemoglobin, insulin resistance and cardiovascular disease risk factors such as hyperlipidemia and high blood pressure.Citation122,Citation123 It is not yet known how quickly weight is regained on cessation of treatment, however in trials in which patients were re-randomized to placebo after one year of treatment they regained some but not all of the weight lost from baseline.Citation124 In the UK, Clinical Excellence guidelines currently recommend that orlistat should not be continuously used for more than 24 months.Citation125 Such precautions are advisable because of the limited data available on the effect of orlistat administration for longer than two years (only the XENDOS study administered the drug continuously for 48 months) and side effect issues. Specifically, orlistat has shown to slightly impair the absorption of liposoluble vitamins A, E, and β-carotene,Citation116,Citation126 however, vitamin supplementation is only required in a minority of patients. Orlistat accelerates gastric emptying, this could lead to exaggerated postprandial hyperglycemia,Citation127 and the presence of undigested fat in the bowels causes side effects (such as diarrhea, abdominal pain, oily stools and fecal spotting) that limit use of orlistat.Citation128 Additionally, chronic GI ailments like irritable bowel syndrome are clear contraindications for its use. These issues, along with the potential for abuse of this drug as a purgative, have caused some concern. Nonetheless, a half dose of orlistat (Alli®, 60 mg rather than 120 mg 3 times daily) has been approved in Australasia, USA and the EU for over-the-counter use.Citation128 Data from very recent studies report that the administration of half dose of orlistat in conjunction with a reduced calorie, lower-fat diet to overweight and obese participants significantly reduced their body weight (5.96 kg vs 3.91 kg) waist circumference and visceral fat (15.7% vs 9.4%).Citation129,Citation130 It is important to note that both studies this dose was well tolerated by participants. To summarize, orlistat in conjunction with behavioral modifications could become useful therapies for the treatment of obesity and/or hyperlipidemia.Citation118

Panclicins

Panciclins A, B, C, D, and E are pancreatic lipase inhibitors isolated from Streptomyces sp. NR 0619. Structurally, panclicins A, B, C, D, and E are analogs (but not irreversible inhibitors) of tetrahydrolipstatin, which contains a β-lactone and an N-formyl leucine ester. The IC50 of panclicins A, B, C, D, and E for porcine pancreatic lipase are 2.9, 2.6, 0.62, 0.66, and 0.89 μM, respectively.Citation131 To date, no studies in animal models have been performed.

Ebelactones

Ebelactone B, which is obtained from Streptomyces aburaviensis, produces potent inhibition of pancreatic lipase. When administered (10 mg/kg, 60 min prior to feeding) to rats fed a high fat diet, it inhibited fat intestinal absorption in a dose-dependent manner. It also decreased plasmatic levels of TG and cholesterol. No data on animal weight or adiposity are reported.Citation132

Vibralactone

Vibralactone is a compound isolated from the culture broth of the polypore Boreostereum vibrans. In vitro it inhibits pancreatic lipase with an IC50 of 0.4 μg/mL.Citation133 Studies in animal models are required to test vibralactone’s effectiveness and possible undesirable effects.

Drugs that interfere with carbohydrate absorption

Inhibition of α-amylase and brush border disaccharidases would lead to decreased absorption of all the main carbohydrates in the diet (glucose absorption would not be affected). This in theory would have several benefits, as blocking these enzymes would decrease the absorption of calories thereby promoting weight loss. These compounds have pharmacological potential for helping with weight loss and then maintaining weight without a dramatic reduction in carbohydrate intake. In addition, since carbohydrate absorption is affected, these products would reduce the magnitude of postprandial glucose and insulin responses to dietary carbohydrates. The modulation of this response could prove to be clinically useful in the management of diabetic individuals. α-amylase inhibition delays gastric emptying by increasing the amount of undigested carbohydrate in the ileum.Citation134,Citation135 Therefore, amongst other effects, amylase inhibition could modulate GI function and gut peptide release, strengthening satiety and decreasing food intake by mechanisms including reduced gastric emptying.

Acarbose

Acarbose (Bay g 5421, Glucobay®, Precose®, Prandase®; Bayer) is a pseudotetrasaccharide that inhibits intestinal α-glucosidase reversibly at the brush border of intestinal mucosa. As a consequence, the transformation of disaccharides to monosaccharides is prevented, the uptake of monosaccharides is retarded and thus postprandial insulin and glucose levels are reduced.Citation136,Citation137 A study by Samulitis et alCitation138 showed that in vitro, acarbose (4 μM) strongly inhibited the activities of α-amylase and sucrase (98 and 63%, respectively). At a higher concentration (200 μM) it also inhibited isomaltase activity (28%) with negligible effects on trehalase and lactase activities. Reported adverse reactions are rare with this drug. Gradual dose increments prevent GI side effects. Studies in rats have reported a dose-dependent reduction of weight gain.Citation139 The administration of acarbose to weight-reduced women limited weight regain.Citation140 In a one year, double-blind, randomized, placebo-controlled study in type 2 diabetes subjects, the individuals receiving acarbose lost 0.5 kg while the placebo group gained 0.3 kg.Citation141 Administration of acarbose (150 mg/day) to women with polycystic ovary syndrome significantly reduced body weight and BMI.Citation142Citation144

Deoxynojirimycin (DNJ)

DNJ is a polyhydroxylated alkaloid isolated from mulberry trees which act as a competitive inhibitor of small-intestinal brush-border α-glucosidase.Citation145 Recent reports have considered sericulture products containing DNJ to be suitable for use as functional foods and food additives. In diabetic rats, the administration of DNJ (20 mg/kg) prevents weight gain.Citation146 Synthetic derivatives of DNJ have been developed; they include competitive inhibitors BAY o 1248 (emiglitate) and BAY m 1099 (miglitol). In vitro, both compounds are very potent α-glucosidase inhibitors. At doses ranging from 0.1 to 5 μg/mL, they inhibit sucrase (up to 97%) and glucoamylase (up to 96%). BAY m 1099 also reduced lactase activity (up to 56%). Interestingly, none of these compounds seem to inhibit α-amylase. In contrast to acarbose, the DNJ derivatives at high concentrations (20 to 200 μM) considerably inhibited trehalase and lactase (a β-galactosidase) activities.Citation138 When administered to diabetic rats, BAY o 1248 inhibited weight gain in animals fed a diet high in starch while it did not have any effect on animals fed with glucose.Citation147 In support of findings obtained from animal experiments, BAY o 1248 (10 mg) and BAY m 1099 (50 mg) delayed sucrose absorption and prevented post prandial increases in glucose in healthy male volunteers.Citation148 However, 60% of participants reported intestinal side effects such as flatulence and diarrhea,Citation149 an undesirable effect due to increased amounts of fermentable (undigested) carbohydrates.

Extracts of black, green, and mulberry teas

In vitro studies suggest that extracts of black, green, and mulberry teas could interfere with carbohydrate and TG absorption due to their ability to inhibit α-amylase,Citation150 α-glucosidase,Citation151 sodium-glucose transporters,Citation152 and pancreatic lipase.Citation153 Administration of a combination of green (0.1 g), black (0.1 g), and mulberry (1.0 g) tea leaves which contained approximately 5 mg DNJ-type compounds, 100 mg epicatechin gallate, 300 mg epigallocatechin gallate, and 100 mg theaflavin to humans reduced carbohydrate (derived from starch) absorption by 25%.Citation153 To date, no in vivo studies have been carried out.

Phaseolus vulgaris L

The purified, non-toxic (P. vulgaris contains toxic substances) extract of P. vulgaris (kidney bean) contains large amounts of phaseolamine (Phase 2®; previously sold as Phaseolamin 2250®, referring to 1 g of the product blocking 2250 starch calories, DEcarb®), a glycoprotein that inhibits α-amylase in a non competitive manner.Citation154,Citation155 In the US, several different preparations are commercially available for the treatment of obesity. In vitro studies have demonstrated that phaseolamine binds to α-amylase forming a 1:1 complex inhibiting the enzyme. In rats intragastric phaseolamine administration reduces post-prandial as well as basal plasma glucose levels.Citation156Citation158 In addition, phaseolamine reduces food intake and consequently body weight.Citation139,Citation157,Citation159,Citation160 Apart from the inhibition of α-amylase, P. vulgaris extract seems to stimulate CCK release, and interfere with central mechanisms that regulate food intake and food palatability.Citation161 Administration of large doses of phaseolamine impairs the growth rate of rats.Citation162 Studies performed in humans have shown contradictory results. For instance, three studies have failed to show any measurable inhibition of starch hydrolysis or significant weight loss in vivo,Citation155,Citation163Citation165 suggesting either the existence of an alternate route capable of degrading starch or insufficient amounts of inhibitors reaching the substrate. Subsequent studies showed that intraduodenal administration of the partially purified inhibitor significantly inhibited α-amylase activity during the ingestion of a starch diet.Citation166 Additional studies in normoglycemic and diabetic individuals found that phaseolamine administration produced an earlier reduction of postprandial glucose levels than controls, with 57% lower glucose absorption.Citation167,Citation168 Acute administration of 1.5 g of phaseolamine to healthy participants blocked the absorption of 66% of carbohydrates present in a standard meal.Citation169 A 30-day, double-blind, placebo-controlled clinical trial for weight loss that compared Phase 2 versus placebo reported a 4% loss of body weight compared with 0.47% in the placebo group. This was accompanied by a 10% reduction in body fat in the experimental group.Citation170 In 2007, Celleno et alCitation171 and Udani and SinghCitation172 conducted randomized, double-blinded, placebo-controlled studies on normal and overweight male and female volunteers during which some participants were prescribed a high carbohydrate diet. After 1 month of chronic administration (445 to 1000 mg/day) participants receiving P. vulgaris extract showed a significant reduction in both total body mass and BMI compared to control, accompanied by changes in body composition. This was shown by significant reductions in total fat mass, fat deposition, and waist/hip/thigh circumferences while maintaining lean body mass. At the moment, the long-term consequences of intraluminal amylase inhibition are not known. Therefore longer studies with a larger pool of subjects are required to investigate these effects and validate the above-mentioned findings.

Both anti-lipase and anti-amylase activity

Berry polyphenols

Berry polyphenols, such as anthocyanins and ellagitannins have been shown to reduce postprandial hyperglycemia.Citation173 Although in vitro anthocyanins can directly induce secretion of insulin from pancreatic cells,Citation174 their main effect on postprandial hyperglycemia seems mainly due to inhibition of α-glucosidase and α-amylase.Citation175 In addition, in vitro this extract also exerts inhibitory activity on pancreatic lipase. Ellagitannin-rich extracts such as (raspberry, strawberry, cloudberry and arctic bramble) seem to be the most effective at inhibiting lipase.Citation176 Some published data suggest that extract-induced fecal lipid excretion is associated with reductions in weight gain and changes in TG metabolism,Citation97,Citation177 while other studies report no significant correlations.Citation178 The lack of effects found in some studies could be due to compensatory increases in lipase secretion similar to those seen in studies on condensed tannins in rats.Citation90 The demonstration of lipase inhibition in vivo by berry components needs to be fully demonstrated before there can be any serious investigation of their weight management potential.

Cyclocarya paliurus (Batal.) Iljinskaja

C. paliurus is a tree found in the highlands of southern China. It is used as a folk remedy for several ailments. Cyclocarioside A, II and III are triterpenoid saponins isolated from the leaves of C. paliurus. It is known that triterpenoid saponins exhibit an insulin-like activity in adipocytes, in vivo and in vitro.Citation179 Therefore, this could be one mechanism responsible for the beneficial effects of these compounds. In vitro, C. paliurus extract showed inhibitory activity toward pancreatic lipase, with an IC50 of 9.1 μg/mL.Citation180 Administration of C. paliurus extract (250 mg/kg) to mice after a load of dietary fat suppressed the expected increase in plasma triacylgycerol levels.Citation180 Taken together these results suggest that the hypolipemic action of C. paliurus extract is probably due to lipase inhibition. In vitro studies have shown α-glucosidase inhibitory activity at the dose of 5 μg/mL. Administration of a C. paliurus extract (250 mg/kg) to mice suppressed the expected increase of blood glucose level following sucrose administration.Citation181 In addition, the oscillations in blood glucose levels found in genetically hyperglycemic obese KK-AY mice were significantly lower when C. paliurus (2 g/day) extract was administered daily for 3 weeks. To date, no research has been conducted on the hypoglycemic effect of this extract in clinical settings

Green tea

In Asia, green tea is widely consumed and for centuries has been thought to exert significant health promoting effects.Citation182 The long-term consumption of green tea and its extract (GTE) (commercially available as pills, patches, gums, mints, extracts, and ice creams) has been associated with weight loss mainly through a thermogenic mechanism. Citation183 Compared to other teas, green tea catechins have been the most extensively investigated. Because green tea is derived from an oxidation-free process, high levels of catechins are retained. In contrast, the full fermentation processes used to produce black tea significantly reduce catechins levels.Citation184 The main active ingredients in GTE: the catechins epigallocatechin gallate (EGCG; Teavigo®), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC) are responsible for many of the beneficial effects of green tea.Citation185,Citation186 In vitro data suggest that the anti-obesity effects of green tea could in part be mediated through the inhibition of adipocyte division and maturation.Citation187Citation189 There is also evidence that green tea could reduce glucose and fat absorption by inhibiting GI enzymes involved in nutrient digestion.Citation190,Citation191 Juhel et alCitation192 reported that in vitro the green tea extract AR25 (Exolise®; standardized at 25% catechins) effectively inhibited gastric and pancreatic lipase activities. In addition, tea polyphenols have been shown to inhibit α-amylase and α-glucosidase in vitro.Citation191 It has been shown that green tea catechins reduced α-amylase and sucrase activities in rat intestine.Citation191 A study performed in streptozotocin-induced diabetic rats showed that addition of green tea extracts to the diet (0.01% and 0.2% of diet) significantly reduced maltase (both doses) as well as saccharase and lactase (higher dose) activities.Citation193 Administration of green tea extract (3% of diet) to rats fed a high fat diet decreased body weight gain and visceral fat accumulation, this correlated with an increase in fecal lipids.Citation194 An open study carried out in moderately obese patients showed that administration of AR25 for 3 months decreased body weight and waist circumference by 4.6% and 4.48% respectively.Citation195 Again, these effects could be the result of the aforementioned combination of enzyme inhibition and increased thermogenesis.

Nelumbo nucifera extract (NNE)

N. nucifera Gaertn. is a large aquatic herb widely found in India and China. Its extracts seem to have anti-inflammatory,Citation196 antipyreticCitation197 and antioxidant properties.Citation198 In vitro studies have shown that NNE inhibits lipase and α-amylase activity with an IC50 value of 0.46 mg/mL and 0.82 mg/mL respectively. This effect was dependent upon the phenolic compounds present in the extract since its elimination abolished NNE inhibitory activity.Citation199 In DIO female mice, treatment with NNE (5% of diet) and exercise decreased body weight, parametrial adipose tissue weight and liver TG levels, this effect was not seen in the exercise only group.Citation199 Oral administration of NNE to glucose-fed hyperglycemic and streptozotocin-induced diabetic rats markedly reduced blood sugar levels when compared with control animals. In normal animals, NNE administration improved glucose tolerance and potentiated the action of exogenously injected insulin. To date no studies in humans have been reported.Citation200

Oolong tea catechins

Catechins in oolong tea are reported to prevent DIO by inhibiting small intestine micelle formation,Citation201 limiting the absorption of sugars by inhibiting α-glucosidase activity.Citation202 Epigallocatechin 3-O-gallate (EGCG) is one of the main polyphenols in oolong tea. In vitro, it inhibits pancreatic lipase with an IC50 of 0.349 μM. In addition, flavan-3-ol digallate esters, such as (−)-epigallocatechin-3,5-digallate also possess inhibitory lipase activity with an IC50 of 0.098 μM.Citation203 In DIO mice, oolong tea catechins suppressed increases in body weight, parametrial adipose tissue weights, and adipose cell size by delaying the absorption of dietary fat from the intestine by inhibiting pancreatic lipase activity.Citation73 In a double-blind, placebo-controlled study, 12 weeks daily administration of oolong tea (containing 690 mg of catechins) to normal and overweight males (with daily EI set at 90%) produced a significant reduction in body weight (1.5%), BMI (1.5%), waist circumference (2.0%), and body fat mass (3.7%), compared to the placebo group.Citation204 These results suggest that oolong tea catechin consumption might be useful as an adjuvant during weight loss programs.

Peanut and peanut shell extract (PSE)

An aqueous extract of peanut cotyledons has shown specific inhibitory activity towards pancreatic and human salivary α-amylasesCitation205 and lipases.Citation206 The peanut shell extract also shows inhibitory effects on human lipase, with a dose of 10 mg/mL inhibiting 92% of activity.Citation207 When administered as 1% of a high fat diet, PSE reduced weight gain in normal adult rats without altering food consumption.Citation207

Salacia reticulata

S. reticulata is a climber found in Sri Lanka and India. Its stems and roots are used for diabetes treatment. In Japan, S. reticulata extract is consumed as a food supplement that suppresses postprandial hyperglycemia. The main compounds responsible for α-glucosidase inhibition are salacinolCitation208 and kotalanol.Citation209 S. reticulate polyphenol extracts also inhibit pancreatic lipase with an IC50 of 264 mg/L, and among the constituents isolated from S. reticulata, catechins showed potent inhibitory activity.Citation210 Studies performed in Zucker rats and high-fat diet rats have shown that the oral administration of a S. reticulata extract (125 mg/kg) suppressed body weight gain without affecting food intake.Citation210 To date no human studies have been carried out.

Salix matsudana

S. matsudana (Chinese willow) (one ingredient of Rev Hardcore® and Methyl Ripped®) is a species of willow native to north western China. Its leaves have been used in traditional Chinese medicine for the treatment of several ailments. It has recently been reported that the polyphenol extracts of S. matsudana have anti-obesity actions.Citation211,Citation212 These studies showed that oral administration of polyphenol fractions to DIO mice reduced adiposity and body weight. In vitro analysis revealed that S. matsudana extract inhibited the enzyme α-amylase. In addition, the polyphenol fractions also had an effect on lipid absorption since its presence completely inhibited the intestinal absorption of palmitic acid, a product of oil hydrolysis. The effects of S. matsudana are mainly due to the inhibition of carbohydrate and lipid absorption, and the acceleration of fat mobilization through enhancement of NA-induced lipolysis in adipocytes.Citation211 Although S. matsudana extracts have been shown to have anti-obesity actions in vitro and in rodents, research in humans, especially on the long term effects, is lacking.

Conclusion

Blocking the digestion and absorption of dietary lipids and carbohydrates provides a valuable alternative to other pharmacological approaches to obesity. With the recent withdrawal of sibutramine from the European market, the only globally licensed anti-obesity drug remaining is the lipase inhibitor orlistat. This lipase inhibitor has also now been licensed in many countries for over-the-counter, non-prescription weight control. Clinical data suggest that lipase inhibition produces greater than anticipated reductions in diabetes and cardiovascular risk factors than would be expected to be produced by its effects on body weight alone. However, the effect of blocking lipase action on meal induced satiety signals may produce counterproductive effects on appetite. The clinical implications of this have yet to be determined.

Studies in obese patients suggest that lipase inhibitors may be particularly beneficial for those who can effectively control their food intake and adhere to diet restriction. However for those with more dysregulated eating behavior, appetite-suppressing pharmacotherapy might be more efficacious. The role of lipase inhibition induced GI side effects in clinical weight loss remains to be determined. Do those who use lipase inhibitors learn to avoid dietary fat? Or do they learn to avoid taking the prescription as intended – for example regularly missing doses before the consumption of high fat meals? Little evidence exists on the effects of lipase inhibition on dietary compliance and claims based on this lack substantiation. However, if lipase inhibition does produce beneficial changes in behavior through GI-related side effects, the development of side effect-free lipase inhibitors will be pointless.

For blocking of the inhibition of carbohydrate digestive enzymes, the so-called starch blockers have been available for many years. To date, none of these agents have made a significant contribution to the effective management of obesity. Nonetheless, such products appear to produce beneficial effects on blood glucose levels and may have benefits in obese diabetic populations. Like lipase inhibitors, these agents will not cross the blood–brain barrier and produce CNS related side effects as with traditional appetite suppressant/anti-obesity medication, or nausea associated with newer incretin-based treatments for obesity and diabetes. A major consequence of blocking digestion of carbohydrates in the proximal gut, colonic fermentation, can only lead to increased microbial production of gas in the bowel. The effects of starch blockers on appetite immediately post-meal might weaken those processes of satiety dependent on rapid glucose absorption (during and immediately post-meal). However colonic fermentation may increase late post meal satiety signals mediated by the release of short-chain FFA such as GLP-1 and PYY, and FFA oxidation in the liver. Overall, it can be concluded that no single compound can be considered to be a proven weight control product. Although some of the products reviewed above show potentially promising effects for weight control, for the majority more data are needed to define safety, the optimal dose required, and the actual magnitude of effects that can be expected during use in practice. Moreover, many of these substances may also produce adverse side effects.

For the majority of compounds described here, there are tantalizing but still inconsistent or incomplete data relating to the mechanism of action and benefits for weight control. In the majority of cases effects have been demonstrated in vivo or to a lesser extent in animal models. For lipase inhibitors, although the majority of plant derivatives exert in vitro inhibitory activity, the most promising compounds seem to be those derived from bacterial sources such as lipstatin and its synthetic derivative orlistat. These compounds have proven to reduce body weight in humans without significant side effects. In terms of the inhibition of carbohydrate digestive enzymes, the products that have so far been used with some degree of success in humans for the purpose of weight reduction are acarbose and phaseolamine, the remaining products are still in experimental phases. Finally, some phytochemicals such as green and oolong tea extracts, which inhibit both lipid and carbohydrate digestive enzymes, seem to have some beneficial effects as weight-controlling products.

Improved understanding and evidence on each of the reviewed and other proposed weight control ingredients will guide further research, as well as the selection of ingredients and product formats that can deliver the most attractive and effective benefits to consumers. Ultimately, only randomized, double blinded, placebo-controlled clinical trials of enzyme inhibitors in humans can demonstrate their true potential. For all ingredients purported to be useful in weight control, significant placebo-subtracted weight loss needs be demonstrated at least in the medium term, ie, up to 24 weeks of use. Nonetheless, inhibition of the breakdown of carbohydrate and fat in the GI tract remains a viable means of reducing energy absorption and thus overall energy intake. As such they may prove useful agents in weight management.

Disclosures

The authors declare no conflicts of interest.

References

  • Bray GA Medical consequences of obesity J Clin Endocrinol Metab 2004 89 2583 2589 15181027
  • WHO/Europe The challenge of obesity in the WHO European Region 2005 WHO Copenhagen, Bucharest
  • WHO Obesity and overweight Geneva WHO 2006
  • Wadden TA Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials Ann Intern Med 1993 119 688 693 8363198
  • Rosenbaum M Leibel RL The physiology of body weight regulation: relevance to the etiology of obesity in children Pediatrics 1998 101 525 539 12224659
  • Tong PC Lee ZS Sea MM The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes Arch Intern Med 2002 162 2428 2435 12437401
  • Wadden TA Berkowitz RI Sarwer DB Prus-Wisniewski R Steinberg C Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial Arch Intern Med 2001 161 218 227 11176735
  • Oster G Thompson D Edelsberg J Bird AP Colditz GA Lifetime health and economic benefits of weight loss among obese persons Am J Public Health 1999 89 1536 1542 10511836
  • Goldstein DJ Beneficial health effects of modest weight loss Int J Obes Relat Metab Disord 1992 16 397 415 1322866
  • Foster-Schubert KE Cummings DE Emerging therapeutic strategies for obesity Endocr Rev 2006 27 779 793 17122357
  • Halford JCG Cooper GD Dovey TM Ishii Y Rodgers RJ Blundell JE The psychopharmacology of appetite: targets for potential anti-obesity agents Curr Med Chem 2003 3 283 310
  • Bray GA Greenway FL Current and potential drugs for treatment of obesity Endocr Rev 1999 20 805 875 10605627
  • Carey MC Hernell O Digestion and absorption of fat Semin Gastroint Dis 1992 3 189 208
  • Carey MC Small DM Bliss CM Lipid digestion and absorption Annu Rev Physiol 1983 45 651 677 6342528
  • Nicolosi RJ Wilson TA Lawton C Handelman GJ Dietary effects on cardiovascular disease risk factors: beyond saturated fatty acids and cholesterol J Am Coll Nutr 2001 20 421S 427S 11603652
  • Mukherjee M Human digestive and metabolic lipases-a brief review J Mol Catal, B Enzym 2003 22 369 376
  • Birari RB Bhutani KK Pancreatic lipase inhibitors from natural sources: unexplored potential Drug Discov Today 2007 12 879 989 17933690
  • Hamosh M Lingual and gastric lipases: their role in fat digestion Boca Raton, FL CRC Press 1990
  • Van Gaal L Mertens I Ballaux D Verkade HJ Modern, new pharmacotherapy for obesity. A gastrointestinal approach Best Pract Res Clin Gastroenterol 2004 18 1049 1072 15561638
  • Borgstrom B Erlanson-Albertsson C Hydrolysis of milk fat globules by pancreatic lipase. Role of colipase, phospholipase A2, and bile salts J Clin Invest 1982 70 30 32 7085886
  • Lowe ME The triglyceride lipases of the pancreas J Lipid Res 2002 43 2007 2016 12454260
  • Crenon I Foglizzo E Kerfelec B Pancreatic lipase-related protein type I: a specialized lipase or an inactive enzyme Protein Eng 1998 11 135 142 9605548
  • Lowe ME Properties and function of pancreatic lipase related protein 2 Biochimie 2000 82 997 1004 11099796
  • Sias B Ferrato F Grandval P Human pancreatic lipase-related protein 2 is a galactolipase Biochemistry 2004 43 10138 10148 15287741
  • Reboul E Berton A Moussa M Kreuzer C Crenon I Borel P Pancreatic lipase and pancreatic lipase-related protein 2, but not pancreatic lipase-related protein 1, hydrolyze retinyl palmitate in physiological conditions Biochim Biophys Acta 2006 1761 4 10 16497549
  • Carriere F Barrowman JA Verger R Laugier R Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans Gastroenterology 1993 105 876 888 8359655
  • Armand M Borel P Dubois C Characterization of emulsions and lipolysis of dietary lipids in the human stomach Am J Physiol 1994 266 G372 G381 8166277
  • Armand M Borel P Pasquier B Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum Am J Physiol 1996 271 G172 G183 8760121
  • Armand M Pasquier B Andre M Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract Am J Clin Nutr 1999 70 1096 1106 10584056
  • Phan CT Tso P Intestinal lipid absorption and transport Front Biosci 2001 6 D299 D319 11229876
  • Thomson ABR De Pover A Keelan M Jarocka-Cyrta E Clandinin MT Inhibition of lipid absorption as an approach to the treatment of obesity Rubin B Dennis EA Methods in Enzymology Elsevier San Diego 1997 3 41
  • Shi Y Burn P Lipid metabolic enzymes: emerging drug targets for the treatment of obesity Nat Rev Drug Discov 2004 3 695 710 15286736
  • van Tilbeurgh H Sarda L Verger R Cambillau C Structure of the pancreatic lipase-procolipase complex Nature 1992 359 159 162 1522902
  • Mu H Hoy CE The digestion of dietary triacylglycerols Prog Lipid Res 2004 43 105 133 14654090
  • Englyst KN Englyst HN Carbohydrate bioavailability Br J Nutr 2005 94 1 11 16115326
  • Cummings JH Macfarlane GT Englyst HN Prebiotic digestion and fermentation Am J Clin Nutr 2001 73 415S 420S 11157351
  • Grabitske HA Slavin JL Gastrointestinal effects of low-digestible carbohydrates Crit Rev Food Sci Nutr 2009 49 327 360 19234944
  • Hofbauer KG Molecular pathways to obesity Int J Obes Relat Metab Disord 2002 26 Suppl 2 S18 S27 12174325
  • Weigle DS Pharmacological therapy of obesity: Past, present, and future Clin Endocrinol Metab 2003 88 2462 2469
  • Lissner L Heitmann BL Dietary fat and obesity: evidence from epidemiology Eur J Clin Nutr 1995 49 79 90 7743988
  • Klein S Long-term pharmacotherapy for obesity Obes Res 2004 12 Suppl 163S 166S 15687412
  • Aronne LJ Obesity Med Clin North Am 1998 82 161 181 9457156
  • Miled N Canaan S Dupuis L Digestive lipases: from three-dimensional structure to physiology Biochimie 2000 82 973 986 11099794
  • Ayvazian L Kerfelec B Granon S The lipase C-terminal domain. A novel unusual inhibitor of pancreatic lipase activity J Biol Chem 2001 276 14014 14018 11154696
  • Sebban-Kreuzer C Ayvazian L Juhel C Salles JP Chapus C Kerfelec B Inhibitory effect of the pancreatic lipase C-terminal domain on intestinal lipolysis in rats fed a high-fat diet: chronic study Int J Obes Relat Metab Disord 2003 27 319 325 12629558
  • Yamada Y Kato T Ogino H Ashina S Kato K Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats Horm Metab Res 2008 40 539 543 18500680
  • Bryson A de la Motte S Dunk C Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers Br J Clin Pharmacol 2009 67 309 315 19220279
  • Kopelman P Bryson A Hickling R Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients Int J Obes (Lond) 2007 31 494 499 16953261
  • Kopelman P de HGG Rissanen A Weight loss, HbA(1c) reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) Obesity (Silver Spring) 2010 18 108 115 19461584
  • Slanc P Doljak B Kreft S Lunder M Janes D Strukelj B Screening of selected food and medicinal plant extracts for pancreatic lipase inhibition Phytother Res 2009 23 874 877 19107742
  • Hostettmann K Marston A Saponins Cambridge Cambridge University Press 1995 560
  • Jiang W Li W Han L Biologically active triterpenoid saponins from Acanthopanax senticosus J Nat Prod 2006 69 1577 1581 17125224
  • Yoshizumi K Hirano K Ando H Lupane-type saponins from leaves of Acanthopanax sessiliflorus and their inhibitory activity on pancreatic lipase J Agric Food Chem 2006 54 335 341 16417288
  • Liu W Zheng Y Han L Saponins (Ginsenosides) from stems and leaves of Panax quinquefolium prevented high-fat diet-induced obesity in mice Phytomedicine 2008 15 1140 1145 18768305
  • Fujikawa T Yamaguchi A Morita I Takeda H Nishibe S Protective effects of Acanthopanax senticosus Harms from Hokkaido and its components on gastric ulcer in restrained cold water stressed rats Biol Pharm Bull 1996 19 1227 1230 8889047
  • Gaffney BT Hugel HM Rich PA Panax ginseng and Eleutherococcus senticosus may exaggerate an already existing biphasic response to stress via inhibition of enzymes which limit the binding of stress hormones to their receptors Med Hypotheses 2001 56 567 572 11388770
  • Yi JM Hong SH Kim JH Kim HK Song HJ Kim HM Effect of Acanthopanax senticosus stem on mast cell-dependent anaphylaxis J Ethnopharmacol 2002 79 347 352 11849840
  • Jung HJ Park HJ Kim RG In vivo anti-inflammatory and antinociceptive effects of liriodendrin isolated from the stem bark of Acanthopanax senticosus Planta Med 2003 69 610 616 12898415
  • Deyama T Nishibe S Nakazawa Y Constituents and pharmacological effects of Eucommia and Siberian ginseng Acta Pharmacol Sin 2001 22 1057 1070 11749801
  • Brekhman II Dardymov IV New substances of plant origin which increase nonspecific resistance Annu Rev Pharmacol 1969 9 419 430 4892434
  • Li F Li W Fu H Zhang Q Koike K Pancreatic lipase-inhibiting triterpenoid saponins from fruits of Acanthopanax senticosus Chem Pharm Bull (Tokyo) 2007 55 1087 1089 17603209
  • Cha YS Soh JR Kim JW Acanthopanax senticosus extract prepared from cultured cells improves lipid parameters in rats fed with a high fat diet J Korean Soc Nutraceut Food 2003 8 40 45
  • Cha YS Rhee SJ Heo YR Acanthopanax senticosus extract prepared from cultured cells decreases adiposity and obesity indices in C57BL/6J mice fed a high fat diet J Med Food 2004 7 422 429 15671684
  • Lee YJ Chung HY Kwak HK Yoon S The effects of A. senticosus supplementation on serum lipid profiles, biomarkers of oxidative stress, and lymphocyte DNA damage in postmenopausal women Biochem Biophys Res Commun 2008 375 44 48 18671947
  • Park SH Lee SG Kang SK Chung SH Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice Arch Pharm Res 2006 29 768 776 17024851
  • Yoshizumi K Murota K Watanabe S Tomi H Tsuji T Terao J Chiisanoside is not absorbed but inhibits oil absorption in the small intestine of rodents Biosci Biotechnol Biochem 2008 72 1126 1129 18391464
  • Qian XZ Colored Illustrations of Chinese Herbs: Part II Beijing People’s Health Press 1996
  • Kimura H Ogawa S Katsube T Jisaka M Yokota K Antiobese effects of novel saponins from edible seeds of Japanese horse chestnut (Aesculus turbinata BLUME) after treatment with wood ashes J Agric Food Chem 2008 56 4783 4788 18512932
  • Hu JN Zhu XM Han LK Anti-obesity effects of escins extracted from the seeds of Aesculus turbinata BLUME (Hippocastanaceae) Chem Pharm Bull (Tokyo) 2008 56 12 16 18175967
  • Kimura H Ogawa S Jisaka M Kimura Y Katsube T Yokota K Identification of novel saponins from edible seeds of Japanese horse chestnut (Aesculus turbinata Blume) after treatment with wooden ashes and their nutraceutical activity J Pharm Biomed Anal 2006 41 1657 1665 16621416
  • Yoshikawa M Sugimoto S Kato Y Acylated oleanane-type triterpene saponins with acceleration of gastrointestinal transit and inhibitory effect on pancreatic lipase from flower buds of chinese tea plant (Camellia sinensis) Chem Biodivers 2009 6 903 915 19551732
  • Kwon CS Sohn HY Kim SH Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents Biosci Biotechnol Biochem 2003 67 1451 1456 12913286
  • Han LK Kimura Y Kawashima M Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor Int J Obes 2001 25 1459 1464
  • Han LK Takaku T Li J Kimura Y Okuda H Anti-obesity action of oolong tea Int J Obes Relat Metab Disord 1999 23 98 105 10094584
  • Leonhardt M Hrupka B Langhans W New approaches in the pharmacological treatment of obesity Eur J Nutr 1999 38 1 13 10338682
  • Han LK Zheng YN Yoshikawa M Okuda H Kimura Y Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes BMC Complement Altern Med 2005 5 9 15811191
  • Hiroahi I Kauzuo T Yohko Y Saponins from the roots of Platycodon grandiflorum. Part 1: structure of prosapogenins J Chem Soc Perkin Trans 1981 1928 1933
  • Kim KS Ezaki O Ikemoto S Itakura H Effects of Platycodon grandiflorum feeding on serum and liver lipid concentrations in rats with diet-induced hyperlipidemia J Nutr Sci Vitaminol (Tokyo) 1995 41 485 491 8676221
  • Xu BJ Han LK Zheng YN Lee JH Sung CK In vitro inhibitory effect of triterpenoidal saponins from Platycodi Radix on pancreatic lipase Arch Pharm Res 2005 28 180 185 15789748
  • Han L Zheng Y Xu B Okuda H Kimura Y Saponins from Platycodi radix ameliorate high fat diet-induced obesity in mice J Nutr 2002 132 2241 2245 12163669
  • Han LK Xu BJ Kimura Y Zheng Y Okuda H Platycodi radix affects lipid metabolism in mice with high fat diet-induced obesity J Nutr 2000 130 2760 2764 11053518
  • Zhao HL Kim YS Determination of the kinetic properties of platycodin D for the inhibition of pancreatic lipase using a 1,2-diglyceride-based colorimetric assay Arch Pharm Res 2004 27 1048 1052 15554263
  • Zhao HL Sim JS Ha YW Kang SS Kim YS Antiobese and hypolipidemic effects of platycodin saponins in diet-induced obese rats: evidences for lipase inhibition and calorie intake restriction Int J Obes (Lond) 2005 29 983 990 15852049
  • Lee EB Pharmacological activities of crude platycodin J Pharmaceut Soc Korea 1975 19 164 176
  • Chung MS Kim NC Long L Dereplication of saccharide and polyol constituents of candidate sweet-tasting plants: isolation of the sesquiterpene glycoside mukurozioside IIb as a sweet principle of Sapindus rarak Phytochemical Analysis 1997 8 49 54
  • Morikawa T Xie Y Asao Y Oleanane-type triterpene oligoglycosides with pancreatic lipase inhibitory activity from the pericarps of Sapindus rarak Phytochemistry 2009 70 1166 1172 19647280
  • Zheng Q Koike K Han LK Okuda H Nikaido T New biologically active triterpenoid saponins from Scabiosa tschiliensis J Nat Prod 2004 67 604 613 15104490
  • Guo T Liu Q Wang P Zhang L Zhang W Li Y Facile synthesis of three bidesmosidic oleanolic acid saponins with strong inhibitory activity on pancreatic lipase Carbohydr Res 2009 344 1167 1174 19463989
  • Arts IC Hollman PC Polyphenols and disease risk in epidemiologic studies Am J Clin Nutr 2005 81 317S 325S 15640497
  • Griffiths DW The inhibition of digestive enzymes by polyphenolic compounds Adv Exp Med Biol 1986 199 509 516 3799290
  • Horigome T Kumar R Okamoto K Effects of condensed tannins prepared from leaves of fodder plants on digestive enzymes in vitro and in the intestine of rats Br J Nutr 1988 60 275 285 2461730
  • Al-Mamary M Al-Aghbari A Al-Habori M Al-Obeidi A In vivo effects of dietary sorghum tannins on rabbit digestive enzymes and mineral absorption Nutr Res 2001 21 1393 1401
  • Nonaka G Hsu F Nishioka I Structures of dimeric, trimeric, and tetrameric procyanidins from Areca catechu L J Chem Soc Chem Commun 1981 781 784
  • Leontowicz H Gorinstein S Lojek A Comparative content of some bioactive compounds in apples, peaches and pears and their influence on lipids and antioxidant capacity in rats J Nutr Biochem 2002 13 603 610 12550072
  • Akiyama H Sato Y Watanabe T Dietary unripe apple polyphenol inhibits the development of food allergies in murine models FEBS Lett 2005 579 4485 4491 16081068
  • Gosse F Guyot S Roussi S Chemopreventive properties of apple procyanidins on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis Carcinogenesis 2005 26 1291 1295 15790589
  • Sugiyama H Akazome Y Shoji T Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption J Agric Food Chem 2007 55 4604 4609 17458979
  • Yamamoto M Shimura S Itoh Y Ohsaka T Egawa M Inoue S Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, Nomame Herba, on rats fed a high-fat diet Int J Obes Relat Metab Disord 2000 24 758 764 10878683
  • Ardevol A Blade C Salvado MJ Arola L Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes Int J Obes Relat Metab Disord 2000 24 319 324 10757625
  • de Freitas VA Glories Y Laguerre M Incidence of Molecular Structure in Oxidation of Grape Seed Procyanidins J Agric Food Chem 1998 46 376 382 10554249
  • Moreno DA Ilic N Poulev A Brasaemle DL Fried SK Raskin I Inhibitory effects of grape seed extract on lipases Nutrition 2003 19 876 879 14559324
  • Yamakoshi J Saito S Kataoka S Kikuchi M Safety evaluation of proanthocyanidin-rich extract from grape seeds Food Chem Toxicol 2002 40 599 607 11955665
  • Thorsen MA Hildebrandt KS Quantitative determination of phenolic diterpenes in rosemary extracts. Aspects of accurate quantification J Chromatogr A 2003 995 119 125 12800928
  • Ninomiya K Matsuda H Shimoda H Carnosic acid, a new class of lipid absorption inhibitor from sage Bioorg Med Chem Lett 2004 14 1943 1946 15050633
  • Machida K Oyama K Ishii M Kakuda R Yaoita Y Kikuchi M Studies of the constituents of Gardenia species. II. Terpenoids from Gardeniae Fructus Chem Pharm Bull (Tokyo) 2000 48 746 748 10823717
  • Mathews-Roth MM Effect of crocetin on experimental skin tumors in hairless mice Oncology 1982 39 362 364 6813784
  • Abe K Sugiura M Shoyama Y Saito H Crocin antagonizes ethanol inhibition of NMDA receptor-mediated responses in rat hippocampal neurons Brain Res 1998 787 132 138 9518580
  • Ochiai T Ohno S Soeda S Tanaka H Shoyama Y Shimeno H Crocin prevents the death of rat pheochromyctoma (PC-12) cells by its antioxidant effects stronger than those of alpha-tocopherol Neurosci Lett 2004 362 61 64 15147781
  • Lee IA Lee JH Baek NI Kim DH Antihyperlipidemic effect of crocin isolated from the fructus of Gardenia jasminoides and its metabolite Crocetin Biol Pharm Bull 2005 28 2106 2110 16272698
  • Weibel EK Hadvary P Hochuli E Kupfer E Lengsfeld H Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity J Antibiot (Tokyo) 1987 40 1081 1085 3680018
  • Guerciolini R Mode of action of orlistat Int J Obes Relat Metab Disord 1997 21 Suppl 3 S12 S23 9225172
  • Hadvary P Sidler W Meister W Vetter W Wolfer H The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase J Biol Chem 1991 266 2021 2027 1899234
  • Carriere F Renou C Ransac S Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers Am J Physiol Gastrointest Liver Physiol 2001 281 G16 G28 11408251
  • Sternby B Hartmann D Borgstrom B Nilsson A Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine Clin Nutr 2002 21 395 402 12381337
  • Halford JCG Pharmacotherapy for obesity Appetite 2006 6 10 16229924
  • Zhi J Melia AT Guerciolini R Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers Clin Pharmacol Ther 1994 56 82 85 8033498
  • Fernandez E Borgstrom B Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat Biochim Biophys Acta 1989 1001 249 255 2917150
  • Hauptman JB Jeunet FS Hartmann D Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin) Am J Clin Nutr 1992 55 309S 313S 1728845
  • Hussain Y Guzelhan C Odink J van der Beek EJ Hartmann D Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat J Clin Pharmacol 1994 34 1121 1125 7876405
  • Sjostrom L Rissanen A Andersen T Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 1998 352 167 172 9683204
  • Torgerson JS Hauptman J Boldrin MN Sjostrom L Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 2004 27 155 161 14693982
  • Rossner S Sjostrom L Noack R Meinders AE Noseda G Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group Obes Res 2000 8 49 61 10678259
  • Scheen AJ Ernest P New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat Diabetes Metab 2002 28 437 445 12522323
  • Karhunen L Franssila-Kallunki A Rissanen P Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns Int J Obes Relat Metab Disord 2000 24 1567 1572 11126207
  • Ballinger A Peikin SR Orlistat: its current status as an anti-obesity drug Eur J Pharmacol 2002 440 109 117 12007529
  • Melia AT Zhi J Koss-Twardy SG The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers J Clin Pharmacol 1995 35 840 843 8522642
  • O’Donovan D Horowitz M Russo A Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes Diabetologia 2004 47 2208 2214 15662558
  • Filippatos TD Derdemezis CS Gazi IF Nakou ES Mikhailidis DP Elisaf MS Orlistat-associated adverse effects and drug interactions: a critical review Drug Saf 2008 31 53 65 18095746
  • Beaver J Bell JD Thomas EL Orlistat 60 mg in conjunction with diet provides significant reduction in visceral adipose tissue 1st International Congress on Abdominal Obesity Hong Kong 2010
  • Greenway F Smith SR Murray K Orlistat 60 mg demonstrates a significant reduction in visceral adipose tissue at 24 weeks compared with placebo 1st International Congress on Abdominal Obesity Hong Kong 2010
  • Mutoh M Nakada N Matsukuma S Panclicins, novel pancreatic lipase inhibitors. I. Taxonomy, fermentation, isolation and biological activity J Antibiot (Tokyo) 1994 47 1369 1375 7844031
  • Nonaka Y Ohtaki H Ohtsuka E Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat J Enzyme Inhib 1996 10 57 63 8835930
  • Liu DZ Wang F Liao TG Vibralactone: a lipase inhibitor with an unusual fused beta-lactone produced by cultures of the basidiomycete Boreostereum vibrans Org Lett 2006 8 5749 5752 17134263
  • Jain NK Boivin M Zinsmeister AR Brown ML Malagelada JR DiMagno EP Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying Gastroenterology 1989 96 377 387 2463204
  • Jain NK Boivin M Zinsmeister AR DiMagno EP The ileum and carbohydrate-mediated feedback regulation of postprandial pancreaticobiliary secretion in normal humans Pancreas 1991 6 495 505 1719522
  • Salvatore T Giugliano D Pharmacokinetic-pharmacodynamic relationships of Acarbose Clin Pharmacokinet 1996 30 94 106 8906894
  • Hildebrand I Boehme K Frank G Fink H Berchtold P The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on post-prandial blood glucose, serum insulin, and triglyceride levels: dose-time- response relationships in man Res Exp Med 1979 175 87 94
  • Samulitis BK Goda T Lee SM Koldovsky O Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine Drugs Exp Clin Res 1987 13 517 524 2962844
  • Puls W Keup U Krause HP Thomas G Pharmacological significance of glucosidase inhibitors (acarbose) Regulators of intestinal absorption in obesity, diabetes and nutrition in Regulators of intestinal absorption in obesity, diabetes and nutrition Proceedings of Satellite Symposium n 7 Third International Congress on Obesity Siena, Italy Societa Editrice Universo 1981
  • William-Olsson T alpha-Glucosidase inhibition in obesity Acta Med Scand Suppl 1985 706 1 39 3914827
  • Wolever TM Chiasson JL Josse RG Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes Int J Obes Relat Metab Disord 1997 21 756 763 9376887
  • Sonmez AS Yasar L Savan K Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome Hum Reprod 2005 20 175 179 15513975
  • Penna IA Canella PR Reis RM Silva de Sa MF Ferriani RA Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study Hum Reprod 2005 20 2396 2401 16006454
  • Tugrul S Kutlu T Pekin O Baglam E Kiyak H Oral O Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Fertil Steril 2008 90 1144 1148 18377903
  • Asano N Yamashita T Yasuda K Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.) J Agric Food Chem 2001 49 4208 4213 11559112
  • Kong WH Oh SH Ahn YR Kim KW Kim JH Seo SW Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models J Agric Food Chem 2008 56 2613 2619 18363357
  • Madar Z Olefsky J Effect of the alpha-glucosidase inhibitor Bay-O- 1248 on the metabolic response of nondiabetic and diabetic rats to a high-carbohydrate diet Am J Clin Nutr 1986 44 206 211 3728357
  • Cauderay M Tappy L Temler E Jequier E Hillebrand I Felber JP Effect of alpha-glycohydrolase inhibitors (Bay m1099 and Bay o1248) on sucrose metabolism in normal men Metabolism 1986 35 472 477 3517560
  • Hillebrand I Boehme K Graefe KH Wehling K The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man Klin Wochenschr 1986 64 393 396 3517475
  • Hansawasdi C Kawabata J Kasai T Alpha-amylase inhibitors from roselle (Hibiscus sabdariffa Linn.) tea Biosci Biotechnol Biochem 2000 64 1041 1043 10879476
  • Matsui T Yoshimoto C Osajima K Oki T Osajima Y In vitro survey of alpha-glucosidase inhibitory food components Biosci Biotechnol Biochem 1996 60 2019 2022 8988634
  • Kobayashi Y Suzuki M Satsu H Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism J Agric Food Chem 2000 48 5618 5623 11087528
  • Zhong L Furne JK Levitt MD An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers Am J Clin Nutr 2006 84 551 555 16960168
  • Marshall JJ Lauda CM Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, Phaseolus vulgaris J Biol Chem 1975 250 8030 8037 240849
  • Hollenbeck CB Coulston AM Quan R Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro studies Am J Clin Nutr 1983 38 498 503 6414283
  • Kotaru M Iwami K Yeh HY Ibuki F In vivo action of alpha-amylase inhibitor from cranberry bean (Phaseolus vulgaris) in rat small intestine J Nutr Sci Vitaminol (Tokyo) 1989 35 579 588 2699495
  • Tormo MA Gil-Exojo I Romero de Tejada A Campillo JE Hypoglycaemic and anorexigenic activities of an alpha-amylase inhibitor from white kidney beans (Phaseolus vulgaris) in Wistar rats Br J Nutr 2004 92 785 790 15533267
  • Tormo MA Gil-Exojo I Romero de Tejada A Campillo JE White bean amylase inhibitor administered orally reduces glycaemia in type 2 diabetic rats Br J Nutr 2006 96 539 544 16925860
  • Jaffe WG Lette CL Heat-labile growth-inhibiting factors in beans (Phaseolus vulgaris) J Nutr 1968 94 203 210 4966063
  • Pusztai A Grant G Duguid T Inhibition of starch digestion by alpha-amylase inhibitor reduces the efficiency of utilization of dietary proteins and lipids and retards the growth of rats J Nutr 1995 125 1554 1562 7782910
  • Fantini N Cabras C Lobina C Reducing Effect of a Phaseolus vulgaris dry extract on food intake, body weight, and glycemia in rats J Agric Food Chem 2009 14 9316 9323 19731962
  • Maranesi M Carenini G Gentili P Nutritional studies on anti alphaamylase: I) Influence on the growth rate, blood picture and biochemistry and histological parameters in rats Acta Vitaminol Enzymol 1984 6 259 269 6335947
  • Bo-Linn GW Santa Ana CA Morawski SG Fordtran JS Starch blockers–their effect on calorie absorption from a high-starch meal N Engl J Med 1982 307 1413 1416 6182469
  • Carlson GL Li BU Bass P Olsen WA A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man Science 1983 219 393 395 6184780
  • Udani J Hardy M Madsen DC Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract Altern Med Rev 2004 9 63 69 15005645
  • Layer P Carlson GL DiMagno EP Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans Gastroenterology 1985 88 1895 1902 2581844
  • Vinson J Investigation on the efficacy of Phaseolamin 2250, a purified bean extract from Pharmachem Laboratories University of Scranton 2001
  • Layer P Rizza RA Zinsmeister AR Carlson GL DiMagno EP Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus Mayo Clin Proc 1986 61 442 447 2423813
  • Vinson JA Al Kharrat H Shuta D Investigation of an Amylase Inhibitor on Human Glucose Absorption after Starch Consumption The Open Nutraceuticals Journal 2009 2 88 91
  • Meiss DE Ballerini R Effectiveness of Phase 2™, a natural alpha-amylase inhibitor, for weight loss: a randomized double-blind, placebo-controlled study Scripps Clinic Natural Supplements in Evidence-Based Practice Conference 2003
  • Celleno L Tolaini MV D’Amore A Perricone NV Preuss HG A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women Int J Med Sci 2007 4 45 52 17299581
  • Udani J Singh BB Blocking carbohydrate absorption and weight loss: a clinical trial using a proprietary fractionated white bean extract Altern Ther Health Med 2007 13 32 37 17658120
  • Broadhurst CL Polansky MM Anderson RA Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro J Agric Food Chem 2000 48 849 852 10725162
  • Jayaprakasam B Vareed SK Olson LK Nair MG Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits J Agric Food Chem 2005 53 28 31 15631504
  • McDougall GJ Stewart D The inhibitory effects of berry polyphenols on digestive enzymes Biofactors 2005 23 189 195 16498205
  • Maatta-Riihinen KR Kamal-Eldin A Mattila PH Gonzalez-Paramas AM Torronen AR Distribution and contents of phenolic compounds in eighteen Scandinavian berry species J Agric Food Chem 2004 52 4477 4486 15237955
  • Hsu TF Kusumoto A Abe K Polyphenol-enriched oolong tea increases fecal lipid excretion Eur J Clin Nutr 2006 60 1330 1336 16804556
  • Tsuda T Regulation of adipocyte function by anthocyanins; possibility of preventing the metabolic syndrome J Agric Food Chem 2008 56 642 646 18211021
  • Sakurai T Nishimura T Otake N Assamicin I and II, novel triterpenoid saponins with insulin-like activity from Aesculus assamica Griff Bioorg Med Chem Lett 2002 12 807 810 11859008
  • Kurihara H Asami S Shibata H Fukami H Tanaka T Hypolipemic effect of Cyclocarya paliurus (Batal) Iljinskaja in lipid-loaded mice Biol Pharm Bull 2003 26 383 385 12612454
  • Kurihara H Kusumoto A Toyoda Y Hypoglycemic action of Cyclocarya paliurus (Batal.) Iljinskaja in normal and diabetic mice Biosci Biotechnol Biochem 2003 67 877 880 12784631
  • Balentine DA Wiseman SA Bouwens LC The chemistry of tea flavonoids Crit Rev Food Sci Nutr 1997 37 693 704 9447270
  • Wolfram S Wang Y Thielecke F Anti-obesity effects of green tea: from bedside to bench Mol Nutr Food Res 2006 50 176 187 16470636
  • Thielecke F Boschmann M The potential role of green tea catechins in the prevention of the metabolic syndrome – a review Phytochemistry 2009 70 11 24 19147161
  • Sano M Tabata M Suzuki M Degawa M Miyase T Maeda-Yamamoto M Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection Analyst 2001 126 816 820 11445943
  • Mandel SA Amit T Weinreb O Reznichenko L Youdim MB Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases CNS Neurosci Ther 2008 14 352 365 19040558
  • Wolfram S Raederstorff D Wang Y Teixeira SR Elste V Weber P TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass Ann Nutr Metab 2005 49 54 63 15735368
  • Furuyashiki T Nagayasu H Aoki Y Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPAR-gamma2 and C/EBPalpha in 3T3-L1 cells Biosci Biotechnol Biochem 2004 68 2353 2359 15564676
  • Hung PF Wu BT Chen HC Antimitogenic effect of green tea (–)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways Am J Physiol Cell Physiol 2005 288 C1094 C1108 15647388
  • Shimizu M Kobayashi Y Suzuki M Satsu H Miyamoto Y Regulation of intestinal glucose transport by tea catechins Biofactors 2000 13 61 65 11237201
  • Matsumoto N Ishigaki F Ishigaki A Iwashina H Hara Y Reduction of blood glucose levels by tea catechin Biosci Biotechnol Biochem 1993 57 525 527
  • Juhel C Armand M Pafumi Y Rosier C Vandermander J Lairon D Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro J Nutr Biochem 2000 11 45 51 15539342
  • Juskiewicz J Zdunczyk Z Jurgonski A Brzuzan L Godycka-Klos I Zary-Sikorska E Extract of green tea leaves partially attenuates streptozotocin- induced changes in antioxidant status and gastrointestinal functioning in rats Nutr Res 2008 28 343 349 19083430
  • Sogawa M Seura T Kohno S Awa (Tokushima) lactate- fermented tea as well as green tea enhance the effect of diet restriction on obesity in rats J Med Invest 2009 56 42 48 19262013
  • Chantre P Lairon D Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity Phytomedicine 2002 9 3 8 11924761
  • Mukherjee PK Saha K Das J Pal M Saha BP Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera Planta Med 1997 63 367 369 9270384
  • Sinha S Mukherjee PK Mukherjee K Pal M Mandal SC Saha BP Evaluation of antipyretic potential of Nelumbo nucifera stalk extract Phytother Res 2000 14 272 274 10861971
  • Jung HA Kim JE Chung HY Choi JS Antioxidant principles of Nelumbo nucifera stamens Arch Pharm Res 2003 26 279 285 12735685
  • Ono Y Hattori E Fukaya Y Imai S Ohizumi Y Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats J Ethnopharmacol 2006 106 238 244 16495025
  • Mukherjee PK Saha K Pal M Saha BP Effect of Nelumbo nucifera rhizome extract on blood sugar level in rats J Ethnopharmacol 1997 58 207 213 9421256
  • Muramatsu K Fukuyo M Hara Y Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats J Nutr Sci Vitaminol (Tokyo) 1986 32 613 622 3585557
  • Ikeda I Imasato Y Sasaki E Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats Biochim Biophys Acta 1992 1127 141 146 1643098
  • Nakai M Fukui Y Asami S Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro J Agric Food Chem 2005 53 4593 4598 15913331
  • Nagao T Komine Y Soga S Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men Am J Clin Nutr 2005 81 122 129 15640470
  • Irshad M Sharma CB Purification and properties of an alpha-amylase protein-inhibitor from Arachis hypogaea seeds Biochim Biophys Acta 1981 659 326 333 6167287
  • Hochstrasser K Feuth H Werle E Isolierung und charakterisierung eines lipasehemmstoffes aus lipiden von Arachis hypogaea Hoppe- Seyler’s Zeitschrift fur Physiologische Chemie 1972 353 855 860 5052944
  • Moreno DA Ilic N Poulev A Raskin I Effects of Arachis hypogaea nutshell extract on lipid metabolic enzymes and obesity parameters Life Sci 2006 78 2797 2803 16337240
  • Yoshikawa M Murakami T Shimada H Salacinol, potent antidiabetic principle with unique thiosugar sulfonium sulfate structure from the Ayurvedic traditional medicine Salacia reticulata in Sri Lanka and India Tetrahedron Lett 1997 38 8367 8370
  • Yoshikawa M Murakami T Yashiro K Matsuda H Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata Chem Pharm Bull (Tokyo) 1998 46 1339 1340 9734318
  • Yoshikawa M Shimoda H Nishida N Takada M Matsuda H Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats J Nutr 2002 132 1819 1824 12097653
  • Han LK Sumiyoshi M Zhang J Anti-obesity action of Salix matsudana leaves (Part 1). Anti-obesity action by polyphenols of Salix matsudana in high fat-diet treated rodent animals Phytother Res 2003 17 1188 1194 14669254
  • Han LK Sumiyoshi M Zheng YN Okuda H Kimura Y Anti-obesity action of Salix matsudana leaves (Part 2). Isolation of anti-obesity effectors from polyphenol fractions of Salix matsudana Phytother Res 2003 17 1195 1198 14669255
  • Han L Nose R Li W Reduction of fat storage in mice fed a high-fat diet long term by treatment with saponins prepared from Kochia scoparia fruit Phytother Res 2006 20 877 882 16892459